PriceTargets.com logo

Magenta Therapeutics - MGTA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.50
  • Forecasted Upside: 344.39%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.79 As of 03/24/2023 01:00 AM ET
▲ +0.01 (1.29%)

This chart shows the closing price for MGTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Magenta Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGTA

Analyst Price Target is $3.50
▲ +344.39% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Magenta Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $8.00 and a low forecast of $1.00. The average price target represents a 344.39% upside from the last price of $0.79.

This chart shows the closing price for MGTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Magenta Therapeutics. This rating has held steady since December 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/31/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2023WedbushReiterated RatingNeutral$1.00Low
2/28/2023HC WainwrightInitiated CoverageNeutralLow
1/26/2023BTIG ResearchDowngradeBuy ➝ NeutralLow
1/26/2023CowenReiterated RatingOutperform ➝ Market PerformLow
1/26/2023WedbushDowngradeOutperform ➝ NeutralLow
12/21/2022BTIG ResearchLower TargetBuy$6.00 ➝ $3.00Low
8/24/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$2.00Low
5/24/2022The Goldman Sachs GroupLower TargetBuy$3.00 ➝ $2.00Medium
4/18/2022MizuhoLower TargetBuy$17.00 ➝ $8.00High
4/18/2022BTIG ResearchLower TargetBuy$10.00 ➝ $6.00High
1/24/2022B. RileyLower TargetBuy$13.00 ➝ $6.00High
1/5/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$7.00 ➝ $8.00High
11/5/2021BTIG ResearchReiterated RatingBuy$19.00High
8/6/2021BTIG ResearchReiterated RatingBuy$20.00High
8/3/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$16.00 ➝ $7.00High
7/22/2021B. RileyLower TargetHold ➝ Buy$21.00 ➝ $19.00High
6/29/2021Cantor FitzgeraldInitiated CoverageOverweight$20.00High
6/14/2021BTIG ResearchInitiated CoverageBuy$20.00Medium
5/18/2021B. RileyInitiated CoverageBuy$21.00High
5/13/2021MizuhoBoost TargetBuy$16.00 ➝ $17.00High
1/28/2021MizuhoInitiated CoverageBuy$16.00High
1/6/2021MizuhoInitiated CoverageBuy$16.00N/A
10/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightHigh
8/13/2020WedbushReiterated RatingOutperform$22.00Low
6/12/2020WedbushReiterated RatingBuy$22.00Medium
6/8/2020The Goldman Sachs GroupUpgradeNeutral ➝ Buy$15.00High
1/13/2020CowenReiterated RatingBuyLow
12/9/2019CowenReiterated RatingBuyHigh
12/6/2019BTIG ResearchInitiated CoverageBuy$20.00Medium
12/6/2019The Goldman Sachs GroupReiterated RatingNeutral$18.00High
11/13/2019CowenReiterated RatingBuyHigh
11/6/2019CowenReiterated RatingBuyMedium
8/8/2019CowenReiterated RatingBuyMedium
5/10/2019WedbushReiterated RatingOutperform$22.00High
3/24/2019The Goldman Sachs GroupDowngradeBuy ➝ Neutral$17.00 ➝ $16.00High
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ OutperformHigh
7/16/2018CowenInitiated CoverageOutperformHigh
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$18.00High
7/16/2018The Goldman Sachs GroupInitiated CoverageBuy$18.00High
7/16/2018WedbushInitiated CoverageOutperform$22.00High
(Data available from 3/26/2018 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
12/26/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/25/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
Mentions as of
2/24/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2023

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Magenta Therapeutics logo
Magenta Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy. The company was founded by David Scadden, Derrick Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 2015 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $0.79
Low: $0.76
High: $0.80

50 Day Range

MA: $0.72
Low: $0.44
High: $0.86

52 Week Range

Now: $0.79
Low: $0.32
High: $3.56

Volume

215,858 shs

Average Volume

385,734 shs

Market Capitalization

$47.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Magenta Therapeutics?

The following Wall Street analysts have issued research reports on Magenta Therapeutics in the last twelve months: BTIG Research, Cowen Inc, HC Wainwright, Mizuho, The Goldman Sachs Group, Inc., and Wedbush.
View the latest analyst ratings for MGTA.

What is the current price target for Magenta Therapeutics?

4 Wall Street analysts have set twelve-month price targets for Magenta Therapeutics in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 344.4%. Mizuho has the highest price target set, predicting MGTA will reach $8.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $1.00 for Magenta Therapeutics in the next year.
View the latest price targets for MGTA.

What is the current consensus analyst rating for Magenta Therapeutics?

Magenta Therapeutics currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MGTA, but not buy more shares or sell existing shares.
View the latest ratings for MGTA.

What other companies compete with Magenta Therapeutics?

Other companies that are similar to Magenta Therapeutics include NextCure, BeyondSpring, Sensei Biotherapeutics, LifeVantage and Aquestive Therapeutics. Learn More about companies similar to Magenta Therapeutics.

How do I contact Magenta Therapeutics' investor relations team?

Magenta Therapeutics' physical mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company's listed phone number is (857) 242-0170 and its investor relations email address is [email protected] The official website for Magenta Therapeutics is www.magentatx.com. Learn More about contacing Magenta Therapeutics investor relations.